NATCO Pharma Limited (NATCOPHARM.BO)
INR 771.25
(0.63%)
INR 771.25
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 69.06 Billion INR | 22.08% |
| 2022 | 56.57 Billion INR | 10.73% |
| 2021 | 51.09 Billion INR | 6.62% |
| 2020 | 47.91 Billion INR | 4.45% |
| 2019 | 45.87 Billion INR | 6.62% |
| 2018 | 43.03 Billion INR | 15.83% |
| 2017 | 37.15 Billion INR | 60.3% |
| 2016 | 23.17 Billion INR | 27.22% |
| 2015 | 18.21 Billion INR | 31.8% |
| 2014 | 13.82 Billion INR | 15.6% |
| 2013 | 11.95 Billion INR | 10.67% |
| 2012 | 10.8 Billion INR | 19.35% |
| 2011 | 9.05 Billion INR | 27.98% |
| 2010 | 7.07 Billion INR | 27.6% |
| 2009 | 5.54 Billion INR | 5.38% |
| 2008 | 5.26 Billion INR | 25.42% |
| 2007 | 4.19 Billion INR | 19.89% |
| 2006 | 3.49 Billion INR | 13.59% |
| 2005 | 3.07 Billion INR | 7.15% |
| 2004 | 2.87 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 69.06 Billion INR | 22.08% |
| 2023 Q4 | 69.06 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 62.54 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 56.57 Billion INR | 0.0% |
| 2022 FY | 56.57 Billion INR | 10.73% |
| 2022 Q2 | 50.77 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 51.09 Billion INR | 6.62% |
| 2021 Q2 | 50.51 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 51.09 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 47.91 Billion INR | 0.0% |
| 2020 FY | 47.91 Billion INR | 4.45% |
| 2020 Q2 | 51.05 Billion INR | 0.0% |
| 2019 FY | 45.87 Billion INR | 6.62% |
| 2019 Q2 | 44.62 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 45.87 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 43.03 Billion INR | 0.0% |
| 2018 Q2 | 42.89 Billion INR | 0.0% |
| 2018 FY | 43.03 Billion INR | 15.83% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 23.74 Billion INR | 0.0% |
| 2017 Q4 | 37.15 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 37.15 Billion INR | 60.3% |
| 2016 Q2 | 20.7 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 23.17 Billion INR | 27.22% |
| 2016 Q4 | 23.17 Billion INR | 0.0% |
| 2015 Q2 | 16.44 Billion INR | 0.0% |
| 2015 FY | 18.21 Billion INR | 31.8% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 18.21 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q2 | 13.03 Billion INR | 0.0% |
| 2014 FY | 13.82 Billion INR | 15.6% |
| 2014 Q4 | 13.82 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 11.95 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 11.95 Billion INR | 10.67% |
| 2013 Q2 | 12.51 Billion INR | 0.0% |
| 2012 Q4 | 10.8 Billion INR | 0.0% |
| 2012 FY | 10.8 Billion INR | 19.35% |
| 2012 Q2 | 10.35 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 9.05 Billion INR | 0.0% |
| 2011 FY | 9.05 Billion INR | 27.98% |
| 2010 FY | 7.07 Billion INR | 27.6% |
| 2009 FY | 5.54 Billion INR | 5.38% |
| 2008 FY | 5.26 Billion INR | 25.42% |
| 2007 FY | 4.19 Billion INR | 19.89% |
| 2006 FY | 3.49 Billion INR | 13.59% |
| 2005 FY | 3.07 Billion INR | 7.15% |
| 2004 FY | 2.87 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | -7.148% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 84.677% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -142.291% |
| Granules India Limited | 55.2 Billion INR | -25.092% |
| Indoco Remedies Limited | 21.44 Billion INR | -222.013% |
| Achyut Healthcare Limited | 309.52 Million INR | -22212.792% |
| Ajanta Pharma Limited | 46.38 Billion INR | -48.894% |
| Alkem Laboratories Limited | 155.74 Billion INR | 55.658% |
| Alpa Laboratories Limited | 1.82 Billion INR | -3681.752% |
| Brooks Laboratories Limited | 904.45 Million INR | -7535.878% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -540.642% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -802.634% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -468.95% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 82.178% |
| Eris Lifesciences Limited | 70.48 Billion INR | 2.022% |
| FDC Limited | 24.68 Billion INR | -179.824% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 51.901% |
| Gufic Biosciences Limited | 10.92 Billion INR | -532.132% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -492.761% |
| Ipca Laboratories Limited | 111.01 Billion INR | 37.788% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -3081.483% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -3776.14% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -4477.689% |
| Laurus Labs Limited | 83.87 Billion INR | 17.655% |
| Lupin Limited | 239.97 Billion INR | 71.22% |
| Mankind Pharma Limited | 119.63 Billion INR | 42.271% |
| Medicamen Biotech Limited | 2.94 Billion INR | -2244.915% |
| Medico Remedies Limited | 961.95 Million INR | -7079.457% |
| Megasoft Limited | 3.65 Billion INR | -1787.484% |
| Piramal Pharma Limited | 153.11 Billion INR | 54.896% |
| RPG Life Sciences Limited | 5.12 Billion INR | -1246.599% |
| Sigachi Industries Limited | 6.94 Billion INR | -894.92% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 91.919% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -206.39% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -1606.676% |
| Unichem Laboratories Limited | 31.69 Billion INR | -117.909% |
| Wanbury Limited | 3.43 Billion INR | -1910.608% |
| Windlas Biotech Limited | 6.26 Billion INR | -1002.88% |
| ZIM Laboratories Limited | 4.46 Billion INR | -1445.648% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 76.414% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -1240.925% |
| Divi's Laboratories Limited | 154.7 Billion INR | 55.357% |
| Hester Biosciences Limited | 6.62 Billion INR | -942.701% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -769.417% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -1782.489% |
| Bal Pharma Limited | 3.2 Billion INR | -2055.598% |
| Strides Pharma Science Limited | 58.39 Billion INR | -18.264% |
| Venus Remedies Limited | 6.26 Billion INR | -1001.782% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -167.468% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -215.204% |
| Shilpa Medicare Limited | 30.93 Billion INR | -123.273% |
| Aarti Drugs Limited | 24.32 Billion INR | -183.934% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -207.713% |
| Suven Life Sciences Limited | 2.84 Billion INR | -2324.091% |
| Ind-Swift Limited | 6.54 Billion INR | -955.249% |
| Valiant Laboratories Limited | 3.42 Billion INR | -1915.336% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -72.911% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -193.765% |
| Themis Medicare Limited | 5.66 Billion INR | -1119.297% |
| Hikal Limited | 24.87 Billion INR | -177.68% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 54.144% |
| Sequent Scientific Limited | 15.4 Billion INR | -348.349% |
| Novartis India Limited | 9.24 Billion INR | -646.684% |
| Wockhardt Limited | 76.49 Billion INR | 9.71% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 40.197% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -14568.445% |
| Neuland Laboratories Limited | 18.32 Billion INR | -276.866% |
| Morepen Laboratories Limited | 12.93 Billion INR | -434.045% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -2776.887% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -1971.325% |